The nonthyroidal illness syndrome
The nonthyroidal illness syndrome
批准号:
7537207
负责人:
RONALD Jay KOENIG
金额:
$32.3万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2012-06-30
关键词:
AccountingAcetylationAcuteAddressAdenovirusesAnimalsCell Culture TechniquesCellsChronic DiseaseDefectDevelopmentEndotoxinsEnzymesEuthyroid Sick SyndromesGene DeletionGenesGenetic TranscriptionHepatocyteHumanHypothalamic DiseasesIodothyronine DeiodinaseKnockout MiceLigandsLigationLipopolysaccharidesMedicalMethylationModelingMusOperative Surgical ProceduresOutcomePhosphorylationPost-Translational Protein ProcessingPuncture procedureRecoveryRoleSepsisSerumSeveritiesSeverity of illnessSyndromeTestingThyroid Hormone ReceptorThyroxineTriiodothyronineTriiodothyronine Receptorsbasecytokineimprovedin vivoiodothyronine deiodinase type Imortalitymouse modelnuclear receptor coactivator 1pituitary thyroid axispreventpromoterresponse
中文摘要
描述(由申请人提供):非甲状腺疾病综合征(NTIS),也称为病态甲状腺功能正常综合征,是与任何急性或慢性疾病相关的低血清甲状腺激素(T3)浓度状态,没有下丘脑-垂体-甲状腺轴的内在疾病。NTIS的严重程度与疾病的严重程度直接相关,多项研究表明,NTIS的严重程度是死亡率的一个独立而有力的预测指标。这些研究的长期目标是了解NTIS的潜在机制,并确定是否应该治疗,如果应该治疗,应该采用什么治疗方法。第一个特异性目标将使用细胞培养和体内小鼠模型来解决NTIS特征甲状腺素向T3转化减少的机制。已知1型碘甲状腺原氨酸脱碘酶(D1)的活性和表达会因疾病而降低。这种影响至少部分是由于甲状腺激素受体诱导D1基因Dio1转录的能力有缺陷。探讨D1表达缺陷、低血清T3与甲状腺激素受体辅激活因子功能之间的关系。特异性目标2将使用两种体内NTIS小鼠模型,内毒素给药和败血症,来测试特异性治疗(强制表达甲状腺激素受体共激活因子)是否可以改善NTIS并降低死亡率。特异性目标3将评估NTIS中甲状腺激素受体辅助激活因子功能受损的基础。有待探索的细胞因子或疾病相关的潜在机制包括诱导与共激活因子竞争的共抑制因子、共激活因子再分配到其他基因、共激活因子再分配到细胞的其他区域,以及共激活因子翻译后修饰的异常。非甲状腺疾病综合征(NTIS)的严重程度与疾病的严重程度直接相关,多项研究表明NTIS的严重程度是死亡率的一个独立而有力的预测因子。这些研究将探讨NTIS的治疗是否能改善严重疾病的康复。
英文摘要
DESCRIPTION (provided by applicant): The nonthyroidal illness syndrome (NTIS), also called the sick euthyroid syndrome, is the state of a low serum thyroid hormone (T3) concentration associated with any acute or chronic illness, without intrinsic disease of the hypothalamic-pituitary-thyroid axis. The severity of the NTIS correlates directly with the severity of illness, and multiple studies show that the severity of the NTIS is an independent and powerful predictor of mortality. The long term objectives of these studies are to understand the mechanisms underlying the NTIS and to address whether it should ever be treated, and if so, what the treatment should be. The first Specific Aim will use cell culture and in vivo mouse models to address the mechanisms underlying the decreased conversion of thyroxine to T3 that characterizes the NTIS. The activity and expression of type 1 iodothyronine deiodinase (D1) are known to be decreased by illness. This effect is due at least in part to a defective ability of thyroid hormone receptors to induce transcription of the D1 gene, Dio1. The relationship between defective D1 expression, the low serum T3, and thyroid hormone receptor coactivator function will be investigated. Specific Aim 2 will use two in vivo mouse models of NTIS, endotoxin administration and sepsis, to test whether a specific therapy (forced expression of a thyroid hormone receptor coactivator) can ameliorate the NTIS and decrease mortality rate. Specific Aim 3 will evaluate the basis for impaired thyroid hormone receptor coactivator function in the NTIS. Cytokine or illness-associated potential mechanisms to be explored include induction of corepressors that compete with the coactivators, redistribution of coactivators to other genes, redistribution of coactivators to other regions of the cell, and abnormalities in post-translational modifications of coactivators. The severity of the nonthyroidal illness syndrome (NTIS) correlates directly with the severity of illness, and multiple studies show that the severity of the NTIS is an independent and powerful predictor of mortality. These studies will address whether treatment of the NTIS improves recovery from serious medical illnesses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
-
批准号:9036341
-
项目类别:
-
资助金额:$49.6万
-
财政年份:2013
-
负责人:RONALD Jay KOENIG
-
依托单位:
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
-
批准号:8628804
-
项目类别:
-
资助金额:$48.11万
-
财政年份:2013
-
负责人:RONALD Jay KOENIG
-
依托单位:
In vivo therapy and mechanisms of PAX8-PPARgamma thyroid cancer
-
批准号:8451143
-
项目类别:
-
资助金额:$50.43万
-
财政年份:2013
-
负责人:RONALD Jay KOENIG
-
依托单位:
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
-
批准号:8683123
-
项目类别:
-
资助金额:$29.58万
-
财政年份:2010
-
负责人:RONALD Jay KOENIG
-
依托单位:
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
-
批准号:8118802
-
项目类别:
-
资助金额:$31.82万
-
财政年份:2010
-
负责人:RONALD Jay KOENIG
-
依托单位:
Pax8-PPARgamma regulation of transcription and metabolism in thyroid cancer
-
批准号:8504792
-
项目类别:
-
资助金额:$29.4万
-
财政年份:2010
-
负责人:RONALD Jay KOENIG
-
依托单位:
The nonthyroidal illness syndrome
-
批准号:8090377
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2008
-
负责人:RONALD Jay KOENIG
-
依托单位:
The nonthyroidal illness syndrome
-
批准号:7869284
-
项目类别:
-
资助金额:$31.98万
-
财政年份:2008
-
负责人:RONALD Jay KOENIG
-
依托单位:
Michigan Diabetes Research and Training Center
-
批准号:7501664
-
项目类别:
-
资助金额:$20.43万
-
财政年份:2006
-
负责人:RONALD Jay KOENIG
-
依托单位:
Retinoic acid and regulation of BMP4 in development
-
批准号:7082160
-
项目类别:
-
资助金额:$36.65万
-
财政年份:2003
-
负责人:RONALD Jay KOENIG
-
依托单位:
Retinoic acid and regulation of BMP4 in development
-
批准号:6669352
-
项目类别:
-
资助金额:$34.53万
-
财政年份:2003
-
负责人:RONALD Jay KOENIG
-
依托单位:
Retinoic acid and regulation of BMP4 in development
-
批准号:6909055
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2003
-
负责人:RONALD Jay KOENIG
-
依托单位:
Retinoic acid and regulation of BMP4 in development
-
批准号:6755010
-
项目类别:
-
资助金额:$35.53万
-
财政年份:2003
-
负责人:RONALD Jay KOENIG
-
依托单位:
Retinoic acid and regulation of BMP4 in development
-
批准号:7234318
-
项目类别:
-
资助金额:$36.62万
-
财政年份:2003
-
负责人:RONALD Jay KOENIG
-
依托单位:
MICHIGAN NIDDK BIOTECHNOLOGY CENTER
-
批准号:6381937
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2000
-
负责人:RONALD Jay KOENIG
-
依托单位:
MICHIGAN NIDDK BIOTECHNOLOGY CENTER
-
批准号:6524337
-
项目类别:
-
资助金额:$52.85万
-
财政年份:2000
-
负责人:RONALD Jay KOENIG
-
依托单位:
CORE--CELL AND MOLECULAR BIOLOGY FACILITY
-
批准号:6417657
-
项目类别:
-
资助金额:$19.33万
-
财政年份:2000
-
负责人:RONALD Jay KOENIG
-
依托单位:
MICHIGAN NIDDK BIOTECHNOLOGY CENTER
-
批准号:6231326
-
项目类别:
-
资助金额:$53.0万
-
财政年份:2000
-
负责人:RONALD Jay KOENIG
-
依托单位:
CORE--CELL AND MOLECULAR BIOLOGY FACILITY
-
批准号:6357038
-
项目类别:
-
资助金额:$19.33万
-
财政年份:1999
-
负责人:RONALD Jay KOENIG
-
依托单位:
CORE--CELL AND MOLECULAR BIOLOGY FACILITY
-
批准号:6301018
-
项目类别:
-
资助金额:$16.48万
-
财政年份:1999
-
负责人:RONALD Jay KOENIG
-
依托单位:
海外基金